[ 1 ] Aoki A, Kojima F, Uchida K, et al. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic hemodialysis patients[J]. Geriatr Gerontol Int, 2009, 9(3): 246-252.
[2]
[ 2 ] Adragao T, Herberth J, Monier-Faugere MC, et al. Low bone volume--a risk factor for coronary calcifications in hemodialysis patients[J]. Clin J Am Soc Nephrol, 2009, 4(2): 450-455.
[3]
[ 3 ] Aoyagi K, Ross PD, Orloff J, et al. Low bone density is not associated with aortic calcification[J]. Calcif Tissue Int, 2001, 69(1): 20-24.
[4]
[ 4 ] Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification[J]. Genes Dev, 1998, 12(9): 1260-1268.
[5]
[ 5 ] Adragao T, Pires A, Lucas C, et al. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients[J]. Nephrol Dial Transplant, 2004, 19(6): 1480-1488.
[6]
[ 6 ] Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density[J]. Cell, 1997, 89(2): 309-319.
[7]
[ 7 ] Tousoulis D, Siasos G, Maniatis K, et al. Novel biomarkers assessing the calcium deposition in coronary artery disease[J]. Curr Med Chem, 2012, 19(6): 901-920.
[ 9 ] Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women[J]. J Bone Miner Res, 2001, 16(2): 348-360.
Panizo S, Cardus A, Encinas M, et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway[J]. Circ Res, 2009, 104(9): 1041-1048.
[13]
Ren MY, Sui SJ, Zhang Y, et al. Increased plasma osteoprotegerin levels are associated with the presence and severity of acute coronary syndrome[J]. Acta Cardiol, 2008, 63(5): 615-622.
[14]
Kurnatowska I, Grzelak P, Kaczmarska M, et al. Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients[J]. Nephron Clin Pract, 2011, 117(4): c297-c304.
[15]
Mesquita M, Demulder A, Damry N, et al. Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease[J]. Clin Chem Lab Med, 2009, 47(3): 339-346.
[16]
Holden RM, Beseau D, Booth SL, et al. FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients[J]. Hemodial Int, 2011, 16(1): 53-58.
[17]
Kagami S, Ohkido I, Yokoyama K, et al. Osteoprotegerin affects the responsiveness of fibroblast growth factor-23 to high oral phosphate intake[J]. Clin Nephrol, 2008, 70(4): 306-311.
[18]
Morena M, Dupuy AM, Jaussent I, et al. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients[J]. Nephrol Dial Transplant, 2009, 24(11): 3389-3397.
[19]
Ford ML, Smith ER, Tomlinson LA, et al. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart[J]. Nephrol Dial Transplant, 2012, 27(2): 727-733.
[20]
Bakhireva LN, Laughlin GA, Bettencourt R, et al. Does osteoprotegerin or receptor activator of nuclear factor-κB ligand mediate the association between bone and coronary artery calcification [J]. J Clin Endocrinol Metab, 2008, 93(5): 2009-2012.
